We are live on ! Find out more
BMY icon

Bristol-Myers Squibb

1,598 hedge funds and large institutions have $63.5B invested in Bristol-Myers Squibb in 2017 Q1 according to their latest regulatory filings, with 130 funds opening new positions, 618 increasing their positions, 647 reducing their positions, and 118 closing their positions.

New
Increased
Maintained
Reduced
Closed

20% more call options, than puts

Call options by funds: $2.17B | Put options by funds: $1.81B

10% more first-time investments, than exits

New positions opened: 130 | Existing positions closed: 118

0.21% less ownership

Funds ownership: 70.96%70.75% (-0.21%)

0% less funds holding

Funds holding: 1,6021,598 (-4)

4% less repeat investments, than reductions

Existing positions increased: 618 | Existing positions reduced: 647

9% less capital invested

Capital invested by funds: $69.4B → $63.5B (-$5.92B)

24% less funds holding in top 10

Funds holding in top 10: 5945 (-14)

Holders
1,598
Holders Change
-4
Holders Change %
-0.25%
% of All Funds
39.77%
Holding in Top 10
45
Holding in Top 10 Change
-14
Holding in Top 10 Change %
-23.73%
% of All Funds
1.12%
New
130
Increased
618
Reduced
647
Closed
118
Calls
$2.17B
Puts
$1.81B
Net Calls
+$358M
Net Calls Change
+$243M
Name Holding Trade Value Shares
Change
Change in
Stake
SAM
326
Silvercrest Asset Management
New York
$9.9M -$2.08M -37,883 -17%
TI
327
TT International
United Kingdom
$9.88M +$997K +18,172 New
WAM
328
World Asset Management
Michigan
$9.79M +$1.65M +29,992 +20%
AIA
329
Avalon Investment & Advisory
Texas
$9.75M +$3.55M +64,721 +57%
MC
330
Muhlenkamp & Co
Pennsylvania
$9.69M -$41.7K -760 -0.4%
Baillie Gifford & Co
331
Baillie Gifford & Co
United Kingdom
$9.67M -$474K -8,639 -5%
PP
332
PDT Partners
New York
$9.58M +$5.08M +92,569 +111%
Connor, Clark & Lunn Investment Management (CC&L)
333
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$9.52M -$10.6M -194,084 -53%
CWM
334
CIBC World Markets
New York
$9.5M -$24.1M -439,949 -72%
EAM
335
Edge Asset Management
Washington
$9.38M
LAM
336
Lebenthal Asset Management
New York
$9.35M +$148K +2,706 +2%
NMERB
337
New Mexico Educational Retirement Board
New Mexico
$9.22M -$494K -9,000 -5%
SF
338
Synovus Financial
Georgia
$9.21M -$743K -13,551 -7%
GLRA
339
Gerald L. Ray & Associates
Texas
$9.2M +$457K +8,340 +5%
HCMNY
340
Howard Capital Management (New York)
New York
$9.16M +$366K +6,680 +4%
SAM
341
Securian Asset Management
Minnesota
$9.15M +$47.1K +859 +0.5%
BIA
342
Biondo Investment Advisors
Pennsylvania
$9.15M +$962K +17,539 +16%
Cambridge Investment Research Advisors
343
Cambridge Investment Research Advisors
Iowa
$9.14M -$655K -11,945 -7%
DL
344
Delta Lloyd
Netherlands
$9.1M +$538K +9,802 +6%
BFM
345
Boston Financial Management
Massachusetts
$9.09M -$829K -15,115 -8%
TCM
346
Twin Capital Management
Pennsylvania
$8.84M -$798K -14,550 -8%
CFG
347
Citizens Financial Group
Rhode Island
$8.76M +$2.68M +48,918 +44%
CAI
348
Capital Advisors Inc
Oklahoma
$8.75M +$365K +6,659 +4%
Capital International Investors
349
Capital International Investors
California
$8.72M
UAM
350
UAS Asset Management
New York
$8.53M +$3.89M +70,925 +83%

BMY Hedge Fund Activity: Q1 2017 in Review

1,598 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in Bristol-Myers Squibb (BMY) for Q1 2017, worth a combined $63.5B — down 8.5% from $69.4B a quarter earlier.

Buyers outnumbered sellers: 130 funds opened new BMY positions and 118 closed out — a net gain of 12 holders — while 618 added to existing stakes and 647 trimmed.

The largest buyer was BlackRock, adding an estimated $5.11B. The largest seller was Janus Henderson Investors US, cutting an estimated $809M.

  • 1,598 institutional investors held Bristol-Myers Squibb (BMY) as of Q1 2017, down from 1,602 in Q4 2016.
  • Funds reported $63.5B of Bristol-Myers Squibb stock for Q1 2017, down 8.5% quarter-over-quarter.
  • 130 funds opened new Bristol-Myers Squibb positions in Q1 2017 and 118 closed out, a net change of +12 holders.
  • The largest Bristol-Myers Squibb buyer in Q1 2017 was BlackRock, an estimated $5.11B added.
  • The largest Bristol-Myers Squibb seller in Q1 2017 was Janus Henderson Investors US, an estimated $809M sold.

Based on aggregated 13F filings for Q1 2017.